Trending menu:
Oncology
-
21 November 2019 News
BMS’ CheckMate -915 trial fails to meet one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported that the CheckMate -915 study of Opdivo (nivolumab) and Yervoy (ipilimumab) combination failed to meet one of the co-primary endpoints in patients with melanoma.
-
20 November 2019 News
Morphosys to enrol more patients in tafasitamab’s B-MIND trial
Morphosys has said that an independent data monitoring committee (IDMC) recommended increasing the size of tafasitamab’s Phase III B-MIND clinical trial.
-
19 November 2019 Comment
Can Merck overcome challenges in an immunologically “cold” tumour with Keytruda for prostate cancer?
Prostate cancers are slow-moving tumours and are generally regarded as immunologically “cold”.
-
11 November 2019 Comment
Poseidon reaps success for AstraZeneca’s Imfinzi in non-small cell lung cancer
The trial will continue to assess the additional primary endpoint of overall survival, with data anticipated in 2020.
-
8 November 2019 Comment
AstraZeneca’s Flaura lung cancer results favour further first-line Tagrisso use
An EGFR mutation refers to a mutation (damage) to the portion of the DNA in a lung cancer cell which carries the "recipe" for making EGFR (epidermal growth factor receptor)...
-
8 November 2019 Comment
Ayala plans Phase II cancer studies to start by first half of 2020
The Phase II AL-101 TNBC study will begin in the first half of 2020.
-
7 November 2019 News
4D Pharma reports Phase I/II data for Keytruda-based combination
4D Pharma has reported initial data from an ongoing Phase I/II clinical trial of a combination of its MRx0518 with MSD’s Keytruda in various cancer types.
-
6 November 2019 News
Regeneron provides update on Phase III NSCLC trials of Libtayo
Regeneron Pharmaceuticals has announced that two Phase III clinical trials of Libtayo (cemiplimab) are currently recruiting advanced non-small cell lung cancer (NSCLC) patients.
-
5 November 2019 News
Halozyme stops PEGPH20 development after Phase III trial fails
Halozyme Therapeutics has announced plans to discontinue the development of its investigational cancer drug, PEGPH20, after it failed in the Phase III HALO-301 clinical trial involving metastatic pancreatic cancer patients.
-
5 November 2019 News
Revolution Medicines and Amgen to trial cancer drug combination
Revolution Medicines has entered an agreement with Amgen to assess RMC-4630 in combination with AMG 510 in a Phase Ib clinical trial for the treatment of solid tumours.